imatinib mesylate has been researched along with Granulomatosis, Lipid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abla, O; Weitzman, S | 1 |
| Amin, HM; Garrido-Laguna, I; Janku, F; Kurzrock, R; Trent, JC; Yang, D | 1 |
| Blombery, P; Lade, S; Prince, HM; Wong, SQ | 1 |
| Amoura, Z; Brousse, N; Charlotte, F; Graux, C; Haroche, J; Piette, JC; Salvatierra, J; Wechsler, B | 1 |
4 other study(ies) available for imatinib mesylate and Granulomatosis, Lipid
| Article | Year |
|---|---|
Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Topics: Clinical Trials as Topic; Erdheim-Chester Disease; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Indoles; Inflammation; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Prospective Studies; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Recurrence; Risk; Sulfonamides; Vemurafenib | 2015 |
Response of histiocytoses to imatinib mesylate: fire to ashes.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Diagnosis, Differential; Drug Administration Schedule; Erdheim-Chester Disease; Female; Genes, abl; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Erdheim-Chester disease harboring the BRAF V600E mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Erdheim-Chester Disease; Glutamic Acid; Humans; Imatinib Mesylate; Immunohistochemistry; Interferon-alpha; Male; Middle Aged; Mutation; Piperazines; Prednisolone; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Valine | 2012 |
Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.
Topics: Adult; Benzamides; Erdheim-Chester Disease; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2008 |